| Name | Title | Contact Details |
|---|
Spring Arbor Of Durham is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delta Community Supports is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Delta Community Supports is based in Blue Bell, PA. You can find more information on Delta Community Supports at www.deltaweb.org
Navigate is a purpose-driven employee engagement technology company with a nimble and customer-focused approach to helping organizations, with a mission to spark positive change by applying their technological capabilities to the field that enables them to make the most impact: health and wellbeing. For the past 13 years, Navigate has assisted organizations by connecting their business goals, mission and values with tailored wellbeing solutions for their teams. Navigate is headquartered in West Des Moines, IA. Recognized as a Shortlister Top Vendor for Wellness Providers in 2019 and 2020.
Clinical Automated Office Solutions / CAOS is a Winston Salem, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.